Impact of Tocilizumab Therapy After Switching From Tumor Necrosis Factor (TNF) inhibitors - Prevention of Joint Damage by Tocilizumab in Patients with Inadequate Response to Anti-TNF Therapies

被引：0
|
作者：
Tanaka, Yoshiya [1 ]
Takeuchi, Tsutomu
Amano, Koichi [3 ]
Sato, Eri [4 ]
Nawata, Masao [5 ]
Nagasawa, Hayato [6 ]
Hoshi, Daisuke [7 ]
Saito, Kazuyoshi
Fukuyo, Shunsuke
Hanami, Kentaro [5 ]
Kameda, Hideto
Kurasawa, Takahiko [6 ]
Kaneko, Yuko [2 ]
Yamanaka, Hisashi [4 ]
机构：
[1] Univ Occupat & Environm Hlth, Fukuoka, Japan
[2] Keio Univ, Sch Med, Shinjuku Ku, Tokyo, Japan
[3] Saitama Med Univ, Saitama Med Ctr, Saitama, Japan
[4] Tokyo Womens Med Univ, Inst Rheumatol, Tokyo, Japan
[5] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan
[6] Saitama Med Ctr, Kawagoe, Saitama, Japan
[7] Tokyo Womens Med Univ, Tokyo, Japan
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1239
引用
收藏
页码：S484 / S484
页数：1
相关论文
共 50 条
  • [1] Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritisanti-TNF
    Duran, E.
    Yildirim, B. E. S.
    Karadag, O.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (09) : S8 - S8
  • [2] OUTCOMES AND ECONOMIC IMPACT OF SWITCHING FROM ANTI-TNF TO ANTI-TNF THERAPY COMPARED WITH SWITCHING FROM ANTI-TNF TO VEDOLIZUMAB THERAPY IN PATIENTS WITH IBD
    Chiorean, Michael V.
    Afzali, Anita
    Zhou, Zhou
    Macaulay, Dendy
    Rizzo, Joanne
    Skup, Martha
    Wang, Anthony
    GASTROENTEROLOGY, 2017, 152 (05) : S591 - S591
  • [3] EFFICACY AND SAFETY OF ABATACEPT IN PATIENTS WITH RA AND AN INADEQUATE RESPONSE TO ANTI-TNF THERAPY BY NUMBER OF PRIOR ANTI-TNF THERAPIES USED
    Schiff, M.
    Le Bars, M.
    Gaillez, C.
    Wu, G.
    Poncet, C.
    Genovese, M. C.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2010, 16 (03) : S29 - S30
  • [4] The inadequate anti-tumour necrosis factor (anti-TNF) therapy in patients with ankylosing spondylitis
    Pinar Borman
    Figen Ayhan
    Esma Ceceli
    Rheumatology International, 2010, 30 : 1689 - 1690
  • [5] ECONOMIC IMPACT OF SWITCHING FROM ANTI-TNF THERAPY TO ADALIMUMAB, INFIXIMAB OR OTHER ANTI-TNF COMPARED WITH SWITCHING FROM ANTI-TNF THERAPY TO VEDOLIZUMAB
    Chiorean, Michael
    Afzali, Anita
    Cross, Raymond
    Zhou, Zhou
    Macaulay, Dendy
    Ganguli, Arijit
    Wang, Anthony
    INFLAMMATORY BOWEL DISEASES, 2018, 24 : S51 - S52
  • [6] The inadequate anti-tumour necrosis factor (anti-TNF) therapy in patients with ankylosing spondylitis
    Borman, Pinar
    Ayhan, Figen
    Ceceli, Esma
    RHEUMATOLOGY INTERNATIONAL, 2010, 30 (12) : 1689 - 1690
  • [7] OUTCOMES WITH TOCILIZUMAB IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO ANTI-TUMOR NECROSIS FACTOR-α THERAPY.
    Emery, Paul
    Keystone, Edward
    Tony, Hans-Peter
    Cantagrel, Alain
    van Vollenhoven, Ronald F.
    Sanchez-Ortiz, Adriana
    Vernon, Emma
    Roseti, Stephanie
    Kremer, Joel
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09) : 1087 - 1087
  • [8] TOCILIZUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN RA PATIENTS WITH INADEQUATE RESPONSE TO PRIOR ANTI-TNF THERAPY: THE RADIATE STUDY
    Sanchez, Ortiz A.
    Kissel, K.
    Alecock, E.
    Emery, P.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2010, 16 (03) : S43 - S43
  • [9] Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
    Hirabara, Shinya
    Takahashi, Nobunori
    Fukaya, Naoki
    Miyake, Hiroyuki
    Yabe, Yuichiro
    Kaneko, Atsushi
    Ito, Takayasu
    Oguchi, Takeshi
    Kida, Daihei
    Hirano, Yuji
    Fujibayashi, Takayoshi
    Sugiura, Fumiaki
    Hayashi, Masatoshi
    Funahashi, Koji
    Hanabayashi, Masahiro
    Asai, Shuji
    Ishiguro, Naoki
    Kojima, Toshihisa
    CLINICAL RHEUMATOLOGY, 2014, 33 (09) : 1247 - 1254
  • [10] Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
    Shinya Hirabara
    Nobunori Takahashi
    Naoki Fukaya
    Hiroyuki Miyake
    Yuichiro Yabe
    Atsushi Kaneko
    Takayasu Ito
    Takeshi Oguchi
    Daihei Kida
    Yuji Hirano
    Takayoshi Fujibayashi
    Fumiaki Sugiura
    Masatoshi Hayashi
    Koji Funahashi
    Masahiro Hanabayashi
    Shuji Asai
    Naoki Ishiguro
    Toshihisa Kojima
    Clinical Rheumatology, 2014, 33 : 1247 - 1254
12345